Drug firm Suven Life Sciences has received three product patents for CNS molecules, two from Eurasia and one fromCanada, which could be used for treating various central nervous system disorders.The product patents are valid til2027.The company has received approval for molecules that could be used in the treatment of neurodegenerative disorderslike Parkinson's, Alzheimer's and Schizophrenia,
No comments:
Post a Comment